Document Classification

Section Type: METHODS

Text: In an open-label, phase 3 study, women (age < 71 years) with locally advanced, inflammatory, or large operable breast cancers were randomly assigned in a 1:1 ratio to either a standard anthracycline regimen (six cycles of intravenous fluorouracil 500 mg/m, epirubicin 100 mg/m, and cyclophosphamide 500 mg/m every 21 days [FEC100], or fluorouracil 600 mg/m, epirubicin 75 mg/m, cyclophosphamide 900 mg/m [tailored FEC] starting on day 1 and then every 21 days) or a taxane-based regimen (three cycles of docetaxel 100 mg/m, intravenously infused over 1 h on day 1 every 21 days, followed by three cycles of intravenous epirubicin 90 mg/m and docetaxel 75 mg/m on day 1 every 21 days [T-ET]) at 42 centres in Europe.